FDA releases Merck memo detailing heart risks associated with Vioxx

11/4/2004 | NYTimes.com

The FDA this week released a memo indicating Vioxx might have been linked to nearly 28,000 heart attacks over a four-year period. The memo, which was based on a sample of patient records, compared the likelihood of the attacks, and deaths, with similar risks associated with Pfizer's Celebrex and was the basis of general statements the agency made about Vioxx in August. A Merck spokeswoman indicated the company had not yet seen the FDA study and did not have any comment.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ